Welcome to our dedicated page for OPTIMI HEALTH news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on OPTIMI HEALTH stock.
Optimi Health Corp. (OPTHF) is a leading Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA. The company recently obtained a Drug Establishment Licence (DEL) from Health Canada, confirming compliance with Good Manufacturing Practices (GMP). This allows Optimi to supply MDMA and psilocybin capsules to patients with PTSD and Treatment-Resistant Depression under Australia's Authorized Prescriber Scheme and export to regulated jurisdictions globally. Optimi aims to be the trusted global supplier of safe drug candidates by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.
Optimi Health Corp. has acquired a diverse catalog of psilocybin and functional mushroom strains, expanding its genetic bank significantly. The acquisition, involving 24 psychedelic and nine functional strains, supports its goal of producing safe, EU-GMP psilocybin in its 20,000 square-foot facility in Princeton, British Columbia. This move allows Optimi to provide products for clinical trials and Canada’s Special Access Program. The company aims to enhance research in mental health treatment, positioning itself as a leading supplier in the burgeoning psychedelic industry.
Optimi Health Corp has completed the expansion of its analytical laboratory located in Princeton, British Columbia, designed to ensure consistent dosages of natural psilocybin products meeting FDA and EU-GMP standards. The lab, overseen by Chief Science Officer Justin Kirkland, aims to enhance research capabilities and support clients in drug discovery processes. CEO Bill Ciprick emphasized the importance of this facility for operationalizing psychedelic science and the company's revenue strategy. Optimi aims to lead in supplying safe, high-quality psilocybin mushrooms.
Optimi Health Corp. (OTCQX: OPTHF) announced its support for Health Canada's Notice on psilocybin mushrooms, highlighting the importance of drug quality and GMP standards. CEO Bill Ciprick emphasized the company's commitment to producing natural psilocybin and functional mushrooms from its advanced facilities. Optimi is positioned to become a leader in this market, having received permission to handle large quantities of psilocybin. The company will also celebrate the grand opening of its Princeton facility on May 27, inviting stakeholders from various sectors.
Optimi Health Corp. has received approval from Health Canada to modify its Controlled Substances Dealer’s Licence, allowing for an expanded capacity to produce psilocybin and psilocin at its Princeton facility. The amendment permits possession of up to 5,000 kg of dried psilocybin mushrooms and 100 g of psilocin, aiming to support clinical trials for addiction and mental health treatments. The company’s facility now comprises 20,000 square feet of advanced aeroponics systems. Optimi plans a grand opening event on May 27, 2022, inviting the local community and stakeholders.
Optimi Health Corp. is set to inaugurate its new psilocybin cultivation facility on May 27, 2022, with an event for media and stakeholders. The company aims to become the leading supplier of safe, natural psilocybin, leveraging its GMP-grade facility in Canada. With a dealer's license from Health Canada and partnerships with pharmaceutical entities, Optimi is focused on producing scalable mushroom formulations. The grand opening will be livestreamed on Instagram, welcoming community members to celebrate this significant milestone in the psychedelic industry.
Optimi Health Corp. (OTCQB: OPTHF) has initiated the cultivation of GMP-grade psilocybin mushrooms at its facility in Princeton, British Columbia. This milestone aims to supply safe psilocybin products for clinical trials amid increasing market demand. The company, having secured a Controlled Drugs and Substances Dealers License, is collaborating with the IMPACT Clinical Trial Accelerator Program for research on microdosing psilocybin to address mental health issues. A brand and media launch is set for May 2022.
Optimi Health Corp. (CSE: OPTI, OTCQB: OPTHF) has entered agreements with Kydder Management Group and Generation IACP Inc. for investor relations and market-making services, pending Canadian Securities Exchange approval. Kydder will receive $40,000 monthly for three months, with a renewal option, while GIACP will earn $7,500 monthly for six months, subject to a 3% annual price increase. Optimi is focused on developing functional mushroom products and has received a research exemption for Psilocybin and Psilocin use under Health Canada regulations.
Optimi Health Corp. (CSE: OPTI, OTCQX: OPTHF) has upgraded its common shares to the OTCQX Best Market, enhancing visibility and accessibility for U.S. investors. This upgrade signifies an important milestone for the company, which focuses on developing functional and psychedelic mushroom products for health and wellness. The OTCQX is reserved for established companies meeting high financial standards and best corporate governance practices. Optimi continues its Canadian listing under the symbol OPTI.
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) has launched a line of functional mushroom supplements in Canada. The company utilizes high-quality fruiting body mushrooms, including Lion’s Mane, Reishi, Turkey Tail, Chaga, and Cordyceps, to enhance cognitive and physical well-being. Optimi employs an eight-step extraction process to maximize nutrient absorption. Bill Ciprick, CEO, emphasizes their commitment to quality and vertical integration, with plans to cultivate their own mushroom strains in Princeton, BC. Products are available online and will reach select retailers later this year.
Optimi Health Corp. (OTCQB: OPTHF) launches its line of functional mushroom supplements in Canada, targeting health-conscious consumers. The products include Lion’s Mane, Reishi, Turkey Tail, Chaga, and Cordyceps, known for their health benefits. These supplements are created using a unique eight-hour extraction process to enhance efficacy. Optimi aims for vertical integration by cultivating its own mushroom strains in a new facility in Princeton, British Columbia. The company emphasizes high-quality production and customer accessibility through its website and upcoming retail partnerships.
FAQ
What is the current stock price of OPTIMI HEALTH (OPTHF)?
What is the market cap of OPTIMI HEALTH (OPTHF)?
What is Optimi Health Corp. specialized in?
What recent milestone did Optimi achieve?
What is Optimi's goal in the pharmaceutical industry?
Where is Optimi's manufacturing facility located?
What licenses does Optimi hold?
How does Optimi plan to support global psychedelic research?
What is Optimi's key achievement in terms of export?
What services does Oak Hill Financial Inc. provide to Optimi?
How does Optimi plan to expand its shareholder base?
What makes Optimi unique in the pharmaceutical industry?
